Anti-Gram-negative beta-lactams in jeopardy: The rise of PBP3 mutations
Dear All (and with thanks to Robert Bonomo and Patricia Bradford for guiding me on this newsletter; anything that’s correct is due to Patricia and
16 April 2026
No Comments
R&D Insight
EMA: “Regulatory sandboxes” to explore approval pathways
Dear All, No, EMA has not decided to set up shop on the beach! Rather, the point of this newsletter is that I heard a fascinating
12 March 2026
No Comments
AMR Surveillance Data Challenge – Vivli 2026 Call for Projects!
Dear All, I’ve written before about the Vivli data challenge (2024 edition, 2025 edition) and am pleased to be able to say that there is
14 April 2026
No Comments
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
Note: See also these related newsletters: 20 Feb 2020 (link) on DTR as part of the language of resistance and 7 June 2020 (link) on
13 January 2019
No Comments
GO-Dx: Global One Health Diagnostics Access Compact
Dear All, Building on the concepts of the January 2016 Industry-led Davos Declaration on action on AMR (website;.pdf declaration; yes, it really has been 10
9 April 2026
No Comments
FDA: One pivotal trial (+ confirmatory evidence) is default expectation for approval
Dear All (a wonkish guide to something you may have thought was obvious AND with thanks to Aaron Dane for co-authoring this newsletter), In a
1 March 2026
No Comments
CARB-X seeks new Chief of R&D (fully remote, worldwide)
Dear All, A very senior and globally significant leadership opportunity has appeared: CARB-X is seeking to recruit a new Chief of Research & Development! Given CARB-X’s role as
9 March 2026
No Comments
Two new oral drugs for gonorrhea!
Dear All (wonkish … but worth it … get ready to follow the links!), Greetings in the new year! As a marvelous way to end
13 January 2026
No Comments
Extending STEDI to diagnostics: STRIDES
Dear All (and with thanks to Betsy Trainor for co-authoring), The idea of the STEDI values of an antibiotic (its fire extinguisher-like values) comes up
18 June 2025
No Comments
Workshop on diagnostics: Can we drive use by making value visible?
Dear All (and with thanks to Robert Skov for co-authoring this newsletter AND with a wonkish alert for this complicated topic for which a compelling
17 February 2026
No Comments